All articles by Liam Stoker

Liam Stoker

GSK to acquire vaccine technology company Okairos

UK-based pharmaceutical major GlaxoSmithKline (GSK) has purchased Switzerland-based vaccine company Okairos in a deal worth €250m.

US Supreme Court backs Amgen shareholders to sue company as a group

The US Supreme Court has backed Amgen shareholders to sue the company as a group without having to demonstrate that misinformation was used to fraudulently inflate its stock price.

Pharmaceutical science – catching up with Armstrong’s doping Peloton

The exposure of Lance Armstrong’s doping campaign has rocked not only the world of cycling, but also anyone who had any faith in anti-doping pharmacology and detection. Liam Stoker investigates Armstrong’s meticulous use of performance-enhancing drugs, and how pharmaceutical science has finally begun to catch up.

Abbott hepatitis C treatment suppresses virus

Abbott’s interferon-free investigational regimen for the treatment of hepatitis C has successfully suppressed the virus during a Phase IIb study.

US hospitals warned over Medicare fraud

US authorities have warned against hospitals defrauding the Medicare system, citing “troubling indications” that doctors may be using electronic records to inflate payments.

Sanofi multiple sclerosis treatment wins US approval

Sanofi has won US Food and Drug Administration approval for its multiple sclerosis medication Aubagio.

Sanofi dengue fever vaccine shows potential

A vaccine for dengue fever developed by Sanofi has shown the potential to protect against three of the four disease serotypes in a mid-stage trial.

Indian Supreme Court begins final hearing on Glivec patent case

Novartis has taken to the stand in India’s Supreme Court, arguing for patent protection for its cancer drug Glivec in India.

UK health bodies alerted after latest anthrax death

The UK Department of Health has issued a warning to the nation’s National Health Service (NHS) following the death of a second person from anthrax poisoning after injecting heroin.

AstraZeneca pulls obesity drug after allergic reaction

AstraZeneca has decided to discontinue the development of obesity drug AZD2820 after a patient given the drug as part of a Phase I trial suffered an allergic reaction.